Mirum Pharmaceuticals (MIRM) Accounts Payables (2018 - 2026)

Mirum Pharmaceuticals' Accounts Payables history runs 9 years deep, the most recent figure standing at $59.4 million for Q1 2026.

• In Q1 2026, Accounts Payables rose 410.34% year-over-year to $59.4 million; the TTM figure through Mar 2026 stood at $59.4 million (up 410.34% YoY), while the FY2025 annual figure was $9.6 million, down 34.23% from the prior year.
• Accounts Payables was $59.4 million for Q1 2026 at Mirum Pharmaceuticals, up from $9.6 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $59.4 million in Q1 2026 to a low of $4.9 million in Q1 2022.
• Historically, Accounts Payables has averaged $13.4 million across 5 years, with a median of $9.8 million in 2024.
• The sharpest annual moves came in 2025 and 2026: Accounts Payables tumbled 34.23% in 2025, then soared 410.34% in 2026.
• A 5-year view of Accounts Payables shows it stood at $8.7 million in 2022, then fell by 14.66% to $7.4 million in 2023, then surged by 97.11% to $14.6 million in 2024, then sank by 34.23% to $9.6 million in 2025, then jumped by 517.84% to $59.4 million in 2026.
• The last three Accounts Payables figures came in at $59.4 million (Q1 2026), $9.6 million (Q4 2025), and $12.2 million (Q3 2025), per Business Quant data.